Content area
Full text
OXIS Therapeutics, Inc., a wholly owned subsidiary of OXIS International (Nasdaq:OXIS)(Nouveau Marche:OXIS), Portland, Ore., has announced results from the Phase IIA clinical trial of its lead compound, BXT-51072, in patients with mild to moderate ulcerative colitis (UC).
UC is a form of inflammatory bowel disease (IBD) that affects approximately 250,000 patients in the U.S. alone. BXT-51072 is a small molecule that mimics the action of the natural antioxidant enzyme, glutathione peroxidase, thereby blocking the activity of free radicals, the toxic molecules believed to be involved in the damage seen in IBD and other inflammatory diseases.
In the study, a total of 20 patients were enrolled in two dose groups....